May 29, 2020
Long-Term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint(TM)
May 29, 2020
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
May 07, 2020
Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
Apr 27, 2020
I-SPY2 TRIAL Demonstrates Significant Improvement in pCR with Durvalumab and Olaparib with Paclitaxel, (Compared to Chemotherapy Alone) in Women with Stage II/III High-Risk, HER2-Negative Breast Cancer, in HR+ and TNBC Subsets
Apr 16, 2020
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
Mar 30, 2020
Insights into the Global Companion Diagnostics Development Services Market to 2030 - Analysis of Completed, Ongoing and Planned Clinical Trials
Jan 17, 2020
Laura van 't Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
Jan 03, 2020
Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse
Dec 12, 2019
New Data Compare Genomic Profiling Results for Premenopausal Women with Early-Stage Breast Cancer
Nov 19, 2019
Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
Sep 29, 2019
Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)
Aug 12, 2019
New Publication Shows Different Result of Risk Classification between GenesWell BCT and Oncotype DX in Breast Cancer Patients 50 Years Old or Younger.
Aug 07, 2019
KEYTRUDA's Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials
Feb 13, 2019
Global $7.7 Bn Molecular Diagnostics Market 2018-2019 & 2024
Jan 09, 2019
Positive Assessment Issued for Agendia's MammaPrint®
Dec 07, 2018
New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
Dec 04, 2018
Oncology Consultants Join Agendia's FLEX Big Data Registry Study, Helping to Build a Unique Resource for Breast Cancer Research
Nov 28, 2018
Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Testing to Guide Breast Cancer Treatment Management Decisions Across Different Patient Populations and Ages at the 2018 San Antonio Breast Cancer Symposium
Nov 19, 2018
Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test
Nov 14, 2018
Latest Results from the I-SPY 2 Trial at the EORTC-NCI-AACR Symposium Demonstrate Ability of MammaPrint® and BluePrint® to Predict Treatment Response in Breast Cancer Patients